Protalix BioTherapeutics (PLX) Capital Expenditures (2010 - 2026)
Protalix BioTherapeutics' quarterly Capital Expenditures came in at $286000.0 in Q1 2026, down 33.02% year-on-year from $427000.0 in Q1 2025, and up 133.03% quarter-over-quarter from -$866000.0 in Q4 2025.
Protalix BioTherapeutics has reported Capital Expenditures for 17 years, with the latest figure at $286000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 33.02% year-over-year to $286000.0; the trailing twelve-month figure through Mar 2026 stood at $228000.0 (up 174.7% YoY), and the FY2025 full-year result was $369000.0, up 45.28% from the prior year.
- Capital Expenditures for Q1 2026 stood at $286000.0, up from -$866000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $736000.0 in Q3 2024, with the low at -$866000.0 in Q4 2025.
- Average Capital Expenditures over 5 years is $98000.0, with a median of $229000.0 recorded in 2022.
- Year-over-year, Capital Expenditures surged 682.26% in 2023 and plunged 333.82% in 2024.
- Tracing PLX's Capital Expenditures over 5 years: stood at -$62000.0 in 2022, then surged by 682.26% to $361000.0 in 2023, then sank by 267.04% to -$603000.0 in 2024, then tumbled by 43.62% to -$866000.0 in 2025, then surged by 133.03% to $286000.0 in 2026.
- The last three Capital Expenditures figures came in at $286000.0 (Q1 2026), -$866000.0 (Q4 2025), and $498000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 286,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 286,000.00 |
| Mar 31, 2026 | 286,000.00 |
| Dec 31, 2025 | -866,000.00 |
| Dec 31, 2025 | -866,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | -603,000.00 |
| Dec 31, 2024 | -603,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Jun 30, 2024 | -477,000.00 |
| Jun 30, 2024 | -477,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Dec 31, 2023 | 361,000.00 |
| Dec 31, 2023 | 361,000.00 |
| Sep 30, 2023 | -199,000.00 |
| Sep 30, 2023 | -199,000.00 |
| Jun 30, 2023 | 204,000.00 |
| Jun 30, 2023 | 204,000.00 |
| Mar 31, 2023 | 248,000.00 |
| Mar 31, 2023 | 248,000.00 |
| Dec 31, 2022 | -62,000.00 |
| Dec 31, 2022 | -62,000.00 |
| Sep 30, 2022 | 124,000.00 |
| Sep 30, 2022 | 124,000.00 |
| Jun 30, 2022 | -148,000.00 |
| Jun 30, 2022 | -148,000.00 |
| Mar 31, 2022 | 229,000.00 |
| Mar 31, 2022 | 229,000.00 |
| Dec 31, 2021 | 448,000.00 |
| Dec 31, 2021 | 448,000.00 |
| Sep 30, 2021 | 344,000.00 |
| Sep 30, 2021 | 344,000.00 |
| Jun 30, 2021 | 281,000.00 |
| Jun 30, 2021 | 281,000.00 |
| Mar 31, 2021 | 386,000.00 |
| Mar 31, 2021 | 386,000.00 |
| Dec 31, 2020 | -63,000.00 |
| Dec 31, 2020 | -63,000.00 |
| Sep 30, 2020 | 102,000.00 |
| Sep 30, 2020 | 102,000.00 |
| Jun 30, 2020 | 212,000.00 |
| Jun 30, 2020 | 212,000.00 |
| Mar 31, 2020 | 66,000.00 |
| Mar 31, 2020 | 66,000.00 |
| Dec 31, 2019 | -501,000.00 |
| Dec 31, 2019 | -501,000.00 |
| Sep 30, 2019 | 392,000.00 |
| Sep 30, 2019 | 392,000.00 |
| Jun 30, 2019 | 37,000.00 |
| Jun 30, 2019 | 37,000.00 |
| Mar 31, 2019 | 170,000.00 |
| Mar 31, 2019 | 170,000.00 |
| Dec 31, 2018 | -273,000.00 |
| Dec 31, 2018 | -273,000.00 |
| Sep 30, 2018 | 104,000.00 |
| Sep 30, 2018 | 104,000.00 |
| Jun 30, 2018 | 145,000.00 |
| Jun 30, 2018 | 145,000.00 |
| Mar 31, 2018 | 249,000.00 |
| Mar 31, 2018 | 249,000.00 |
| Dec 31, 2017 | 290,000.00 |
| Dec 31, 2017 | 290,000.00 |
| Sep 30, 2017 | 138,000.00 |
| Sep 30, 2017 | 138,000.00 |
| Jun 30, 2017 | 323,000.00 |
| Jun 30, 2017 | 323,000.00 |
| Mar 31, 2017 | 220,000.00 |
| Mar 31, 2017 | 220,000.00 |
| Dec 31, 2016 | 117,000.00 |
| Dec 31, 2016 | 117,000.00 |
| Sep 30, 2016 | 157,000.00 |
| Sep 30, 2016 | 157,000.00 |
| Jun 30, 2016 | 324,000.00 |
| Jun 30, 2016 | 324,000.00 |
| Mar 31, 2016 | 251,000.00 |
| Mar 31, 2016 | 251,000.00 |
| Dec 31, 2015 | 4,000.00 |
| Dec 31, 2015 | 4,000.00 |
| Sep 30, 2015 | 128,000.00 |
| Sep 30, 2015 | 128,000.00 |
| Jun 30, 2015 | 233,000.00 |
| Jun 30, 2015 | 233,000.00 |
| Mar 31, 2015 | 99,000.00 |
| Mar 31, 2015 | 99,000.00 |
| Mar 31, 2014 | 263,000.00 |
| Mar 31, 2014 | 263,000.00 |
| Dec 31, 2013 | 222,000.00 |
| Dec 31, 2013 | 222,000.00 |
| Sep 30, 2013 | 327,000.00 |
| Sep 30, 2013 | 327,000.00 |
| Jun 30, 2013 | 699,000.00 |
| Jun 30, 2013 | 699,000.00 |
| Mar 31, 2013 | 642,000.00 |
| Mar 31, 2013 | 642,000.00 |
| Dec 31, 2012 | 251,000.00 |
| Dec 31, 2012 | 251,000.00 |
| Sep 30, 2012 | 770,000.00 |
| Sep 30, 2012 | 770,000.00 |
| Jun 30, 2012 | 237,000.00 |
| Jun 30, 2012 | 237,000.00 |
| Mar 31, 2012 | 810,000.00 |
| Mar 31, 2012 | 810,000.00 |
| Dec 31, 2011 | 704,000.00 |
| Dec 31, 2011 | 704,000.00 |
| Sep 30, 2011 | 985,000.00 |
| Sep 30, 2011 | 985,000.00 |
| Jun 30, 2011 | 1.41 Mn |
| Jun 30, 2011 | 1.41 Mn |
| Mar 31, 2011 | 2.60 Mn |
| Mar 31, 2011 | 2.60 Mn |
| Dec 31, 2010 | 1.04 Mn |
| Dec 31, 2010 | 1.04 Mn |
| Sep 30, 2010 | 1.34 Mn |
| Sep 30, 2010 | 1.34 Mn |